Low preoperative lymphocyte to monocyte ratio predicts poor cancer-specific survival in patients with esophageal squamous cell carcinoma

术前淋巴细胞与单核细胞比值低预示食管鳞状细胞癌患者癌症特异性生存率差

阅读:1

Abstract

BACKGROUND: Recent studies have shown that the lymphocyte to monocyte ratio (LMR) is a useful predictive factor in various cancers. However, the prognostic value of LMR in patients with esophageal cancer has not been reported yet. The purpose of the current study was to determine the prognostic role of LMR in esophageal squamous cell carcinoma (ESCC). METHODS: Three-hundred and forty-eight patients who had undergone esophagectomy for ESCC were included. A receiver operating characteristic curve for survival prediction was plotted to verify the optimum cut-off point for LMR. Kaplan-Meier method was used to calculate the cancer-specific survival (CSS), the difference was assessed by the log-rank test. Univariate and multivariate analyses were performed to evaluate the prognostic factors. RESULTS: A receiver operating characteristic curve for survival prediction was plotted to verify the optimum cut-off point for LMR, which was 2.93. Patients with LMR ≤2.93 had a significantly worse 5-year CSS than patients with LMR >2.93 (21.2% versus 59.3%, P<0.001). For subgroup analysis, the predictive value of LMR was also significant in patients with T1-2 cancer (P=0.003), T3-4a (P<0.001), and patients with (P=0.044) or without (P<0.001) nodal metastasis. In addition, the predictive value of LMR was also significant stratified by absolute lymphocyte count (P<0.001) and absolute monocyte count (P<0.001). In multivariate analysis, LMR was a significant predictive factor of CSS (P=0.010). CONCLUSION: LMR is still a predictive factor for long-term survival in patients with ESCC. We conclude that 2.93 may be the optimum cut-off point for LMR in predicting survival in ESCC patients.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。